A recent study showed that the combination of an anti-MDM2 and a BET-inhibitor (targeting p53 and Myc) was able to eliminate leukaemic stem cells in a chronic myelogenous leukaemia model (Abraham et al, 2016). Here, MYC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.